Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and
ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …

Background Although several randomised trials in patients with triple-negative breast cancer
have shown that the addition of carboplatin, with or without poly (ADP-ribose) polymerase …

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers,
does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human …

Although tetraarsenic hexoxide is known to exert an anti-tumor effect by inducing apoptosis
in various cancer cells, its effect on other forms of regulated cell death remains unclear …

Although blocking the binding of vascular endothelial growth factor (VEGF) to neuropilin-2
(NRP2) on tumor cells is a potential strategy to treat aggressive carcinomas, a lack of …

Introduction Breast cancer is the most common cancer and the second leading cause of
cancer-related death in women worldwide. Despite the early detection of breast cancer and …

Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

Abstract Treatment protocols for breast cancer depend predominantly on receptor status with
respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and …